Financhill is a comprehensive financial analysis platform that provides stock analysis, market data, investment tools, and educational resources to help investors make informed decisions.

How do I get started with Financhill?

You can start by creating a free account, exploring our stock analysis tools, setting up a watchlist, or trying our 7-day trial for full access to all premium features.

What features does Financhill offer?

Financhill offers stock analysis, technical charts, fundamental data, earnings information, dividend tracking, portfolio management, market screening tools, and educational resources.

How accurate are stock forecasts?

Stock forecasts are based on technical and fundamental analysis but should not be considered as guaranteed predictions. Past performance does not guarantee future results.

How do I analyze RARE stock?

Use our comprehensive analysis tools including technical charts, fundamental metrics, earnings data, and Stock Score to evaluate RARE investment potential.

What is RARE stock price today?

Get real-time RARE stock price, historical data, and price charts on Financhill. Track RARE performance with our advanced analysis tools.

Is RARE a good investment?

Evaluate RARE investment potential using our Stock Score, fundamental analysis, technical indicators, and earnings data. Consider your risk tolerance and investment goals.

How to buy RARE stock?

To buy RARE stock, open a brokerage account, research the company using our analysis tools, and place your order through your broker. Always do your own research before investing.

What is the market cap of RARE?

View detailed market capitalization data and company valuation metrics for RARE on our comprehensive analysis page.

What is the P/E ratio of RARE?

Use our fundamental analysis tools to view RARE P/E ratio and compare valuation metrics with industry peers.

What are RARE earnings?

View RARE earnings data, quarterly results, revenue growth, and profit margins on our comprehensive earnings analysis page. Track earnings trends and analyst estimates.

Back

Ultragenyx Pharmaceutical, Inc. Stock Predictions

The Next AI Breakouts Won't Talk Like ChatGPT

*DISCLOSURE: This is a paid advertisement for Immersed Reg A offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks immersed.com

Sell

RARE
Ultragenyx Pharmaceutical, Inc.

Last Price:

$24.69

Seasonality Move:

2.57%

7 Day Trial

ALL ACCESS PASS

$ 7

This Critical Mineral's Up 122% in the Last 12 Months.

DISCLOSURE: EnergyX's Regulation A offering has been qualified by the SEC. Before investing, carefully review the offering circular, including the risk factors. The offering circular is available at

Ultragenyx Pharmaceutical, Inc. Stock Forecast

Over the next 52 weeks, Ultragenyx Pharmaceutical, Inc. has on average historically risen by 2% based on the past 12 years of stock performance.
Ultragenyx Pharmaceutical, Inc. has risen higher in 4 of those 12 years over the subsequent 52-week period, corresponding to a historical accuracy of 33.33%
Is Ultragenyx Pharmaceutical, Inc. Stock Undervalued?

The current Ultragenyx Pharmaceutical, Inc. [RARE] share price is $24.70. The Score for RARE is 34, which is 32% below its historic median score of 50, and infers higher risk than normal.
RARE is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.

Will Ultragenyx Pharmaceutical, Inc. Stock Go Up Next Year?

Over the next 52 weeks, Ultragenyx Pharmaceutical, Inc. has on average historically risen by 2% based on the past 12 years of stock performance.

Ultragenyx Pharmaceutical, Inc. Stock Rating

Sell

Ultragenyx Pharmaceutical, Inc. (RARE) is a Sell

Is Ultragenyx Pharmaceutical, Inc. overpriced?

Ultragenyx Pharmaceutical, Inc. has risen higher in 4 of those 12 years over the subsequent 52-week period, corresponding to a historical accuracy of 33.33%

Ultragenyx Pharmaceutical, Inc. Stock Price History

Is RARE stock going to rise?

Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and RARE is experiencing buying pressure, which is a positive indicator for future bullish movement.

Stock Information

Stock Info

Exchange:

NASDAQ

Country:

United States

Industry:

Biotechnology

Sector:

Health Care

Type:

stock

Website:

ultragenyx.com

52-Week Data

52-Week High:

46.27

52-Week Low:

18.41

Prediction Charts

Market Cap:

2.4B

Price in USD:

24.70

Volume:

2.7M

Beta:

1.08

Technical Analysis

SMA50:

28.56

SMA100:

30.19

SMA200:

31.70

52-Wk Change:

-46.05%

Stock Predictions

Is Ultragenyx Pharmaceutical, Inc. stock public?

Yes, Ultragenyx Pharmaceutical, Inc. is a publicly traded company.
What is the Ultragenyx Pharmaceutical, Inc. stock quote today?

The Ultragenyx Pharmaceutical, Inc. stock price is 24.70 USD today.
How to buy Ultragenyx Pharmaceutical, Inc. stock online?

You can buy Ultragenyx Pharmaceutical, Inc. shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date	Opening	Closing	Minimum	Maximum
Jan-20	22.12	22.63	22.96	22.00
Jan-21	22.72	22.75	22.98	22.49
Jan-22	22.78	23.40	23.87	22.71
Jan-23	23.37	24.21	24.53	23.16
Jan-26	24.10	24.31	24.90	24.09
Jan-27	24.23	24.62	25.00	24.23
Jan-28	24.96	24.44	24.96	24.33
Jan-29	24.40	24.27	24.70	23.98
Jan-30	24.13	24.07	24.59	23.26
Feb-2	23.56	24.76	24.91	23.56
Feb-3	24.92	24.80	25.82	24.37
Feb-4	25.07	24.69	25.07	24.08
Feb-5	24.59	23.79	24.93	23.76
Feb-6	24.25	24.70	24.87	23.89

Ultragenyx Pharmaceutical, Inc. Earnings

Ultragenyx Pharmaceutical, Inc. Earnings Report: Per Share Ultragenyx Pharmaceutical, Inc. Earnings Q1 Q2 Q3 and Q4 last year and next year.

Ultragenyx Pharmaceutical, Inc. Forecast Revenue Growth

Ultragenyx Pharmaceutical, Inc. Stock Analysis: Historical quarterly revenues per share for Ultragenyx Pharmaceutical, Inc. and historical quarterly revenue growth:

Analysts estimate an earnings increase this quarter of $0.12 per share, a decrease next quarter of $0.00 per share, an increase this year of $1.37 per share, and an increase next year of $2.60 per share.

* Ultragenyx Pharmaceutical, Inc. stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.